{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+Glioblastoma&page=2",
    "query": {
      "condition": "Relapsed Glioblastoma",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+Glioblastoma&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T02:31:27.061Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04238819",
      "title": "A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Relapsed Solid Tumor",
        "Refractory Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Dinutuximab",
          "type": "DRUG"
        },
        {
          "name": "GM-CSF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 47,
      "start_date": "2020-11-09",
      "completion_date": "2025-08-19",
      "has_results": true,
      "last_update_posted_date": "2026-03-02",
      "last_synced_at": "2026-07-23T02:31:27.061Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Oakland, California + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Roseville",
          "state": "California"
        },
        {
          "city": "Santa Clara",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04238819"
    },
    {
      "nct_id": "NCT04978727",
      "title": "A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Medulloblastoma",
        "Glioblastoma Multiforme",
        "Anaplastic Astrocytoma",
        "High-grade Astrocytoma NOS",
        "Anaplastic Oligodendroglioma",
        "Anaplastic Ependymoma",
        "Ependymoma",
        "Diffuse Intrinsic Pontine Glioma"
      ],
      "interventions": [
        {
          "name": "SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 35,
      "start_date": "2022-07-01",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-02",
      "last_synced_at": "2026-07-23T02:31:27.061Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Palo Alto, California • Aurora, Colorado + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04978727"
    },
    {
      "nct_id": "NCT02444546",
      "title": "Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Childhood Astrocytoma",
        "Childhood Atypical Teratoid/Rhabdoid Tumor",
        "Diffuse Intrinsic Pontine Glioma",
        "Glioma",
        "Recurrent Childhood Anaplastic Oligodendroglioma",
        "Recurrent Childhood Brain Neoplasm",
        "Recurrent Childhood Glioblastoma",
        "Recurrent Childhood Medulloblastoma",
        "Recurrent Primitive Neuroectodermal Tumor",
        "Refractory Brain Neoplasm"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Wild-type Reovirus",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "10 Years to 21 Years"
      },
      "enrollment_count": 6,
      "start_date": "2015-06-21",
      "completion_date": "2022-11-21",
      "has_results": false,
      "last_update_posted_date": "2023-04-24",
      "last_synced_at": "2026-07-23T02:31:27.061Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02444546"
    },
    {
      "nct_id": "NCT00795665",
      "title": "Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioma"
      ],
      "interventions": [
        {
          "name": "bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "carmustine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2008-06",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2020-05-12",
      "last_synced_at": "2026-07-23T02:31:27.061Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00795665"
    },
    {
      "nct_id": "NCT02684058",
      "title": "Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Astrocytoma",
        "Anaplastic Astrocytoma",
        "Astrocytoma",
        "Oligodendroglioma, Childhood",
        "Anaplastic Oligodendroglioma",
        "Glioblastoma",
        "Pilocytic Astrocytoma",
        "Giant Cell Astrocytoma",
        "Pleomorphic Xanthoastrocytoma",
        "Anaplastic Pleomorphic Xanthoastrocytoma",
        "Angiocentric Glioma",
        "Chordoid Glioma of Third Ventricle",
        "Gangliocytoma",
        "Ganglioglioma",
        "Anaplastic Ganglioglioma",
        "Dysplastic Gangliocytoma of Cerebrellum",
        "Desmoplastic Infantile Astrocytoma and Ganglioglioma",
        "Papillary Glioneuronal Tumor",
        "Rosette-forming Glioneurona Tumor",
        "Central Neurocytoma",
        "Extraventricular Neurocytoma",
        "Cerebellar Iponeurocytoma"
      ],
      "interventions": [
        {
          "name": "Dabrafenib",
          "type": "DRUG"
        },
        {
          "name": "trametinib",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Months to 17 Years"
      },
      "enrollment_count": 151,
      "start_date": "2017-12-28",
      "completion_date": "2023-04-28",
      "has_results": true,
      "last_update_posted_date": "2023-12-13",
      "last_synced_at": "2026-07-23T02:31:27.061Z",
      "location_count": 10,
      "location_summary": "Orange, California • Washington D.C., District of Columbia • Miami, Florida + 7 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02684058"
    },
    {
      "nct_id": "NCT00016991",
      "title": "ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "gefitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2001-06",
      "completion_date": "2005-04",
      "has_results": false,
      "last_update_posted_date": "2013-06-20",
      "last_synced_at": "2026-07-23T02:31:27.061Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00016991"
    },
    {
      "nct_id": "NCT00116376",
      "title": "Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "AEE788",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2004-01",
      "completion_date": "2005-11",
      "has_results": false,
      "last_update_posted_date": "2015-11-10",
      "last_synced_at": "2026-07-23T02:31:27.061Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • San Francisco, California • Box 3624 Dumc, Trent Drive, Durham, North Carolina + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Box 3624 Dumc, Trent Drive, Durham",
          "state": "North Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00116376"
    },
    {
      "nct_id": "NCT00003876",
      "title": "Internal Radiation Therapy Plus Carmustine Implants in Treating Patients With Recurrent or Refractory Malignant Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "polifeprosan 20 with carmustine implant",
          "type": "DRUG"
        },
        {
          "name": "surgical procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "iodine I 125",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Barrett Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1999-04",
      "completion_date": "2004-05",
      "has_results": false,
      "last_update_posted_date": "2013-06-26",
      "last_synced_at": "2026-07-23T02:31:27.061Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003876"
    },
    {
      "nct_id": "NCT00635557",
      "title": "Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "MPC-6827 + Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Myrexis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2008-03",
      "completion_date": "2011-08",
      "has_results": false,
      "last_update_posted_date": "2011-03-25",
      "last_synced_at": "2026-07-23T02:31:27.061Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Atlanta, Georgia • New York, New York + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00635557"
    },
    {
      "nct_id": "NCT00677716",
      "title": "Dose Confirmation Study of Cotara for the Treatment of Glioblastoma Multiforme at First Relapse",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "131I-chTNT-1/B MAb (Cotara)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Peregrine Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 41,
      "start_date": "2007-07",
      "completion_date": "2011-11",
      "has_results": false,
      "last_update_posted_date": "2014-04-24",
      "last_synced_at": "2026-07-23T02:31:27.061Z",
      "location_count": 3,
      "location_summary": "Phoenix, Arizona • Philadelphia, Pennsylvania • Charleston, South Carolina",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00677716"
    }
  ]
}